Acura Pharmaceuticals amends loan schedule for promissory note
Acura Pharmaceuticals updated its loan schedule with Abuse Deterrent Pharma, LLC, increasing the total outstanding principal to approximately $10.7 million as of June 2026. This amendment details specific terms for additional loans ranging from 2022 to 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day